% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koch:277459,
      author       = {E. A. T. Koch and A. Petzold and A. Wessely and E. Dippel
                      and M. Eckstein and A. Gesierich and R. Gutzmer and J. C.
                      Hassel and H. Knorr and N. Kreuzberg and U. Leiter and C.
                      Loquai and F. Meier and M. Meissner and P. Mohr and C.
                      Pföhler and F. Rahimi and D. Schadendorf$^*$ and M. Schlaak
                      and K.-M. Thoms and S. Ugurel$^*$ and J. Utikal$^*$ and M.
                      Weichenthal and B. Schuler-Thurner and C. Berking and M. V.
                      Heppt},
      title        = {{L}iver-directed treatment is associated with improved
                      survival and increased response to immune checkpoint
                      blockade in metastatic uveal melanoma: results from a
                      retrospective multicenter trial.},
      journal      = {Frontiers of medicine},
      volume       = {17},
      number       = {5},
      issn         = {2095-0217},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2023-01386},
      pages        = {878-888},
      year         = {2023},
      note         = {2023 Oct;17(5):878-888},
      abstract     = {Metastases of uveal melanoma (UM) spread predominantly to
                      the liver. Due to low response rates to systemic therapies,
                      liver-directed therapies (LDT) are commonly used for tumor
                      control. The impact of LDT on the response to systemic
                      treatment is unknown. A total of 182 patients with
                      metastatic UM treated with immune checkpoint blockade (ICB)
                      were included in this analysis. Patients were recruited from
                      prospective skin cancer centers and the German national skin
                      cancer registry (ADOReg) of the German Dermatologic
                      Cooperative Oncology Group (DeCOG). Two cohorts were
                      compared: patients with LDT (cohort A, n = 78) versus those
                      without LDT (cohort B, n = 104). Data were analyzed for
                      response to treatment, progression-free survival (PFS), and
                      overall survival (OS). The median OS was significantly
                      longer in cohort A than in cohort B (20.1 vs. 13.8 months; P
                      = 0.0016) and a trend towards improved PFS was observed for
                      cohort A (3.0 vs. 2.5 months; P = 0.054). The objective
                      response rate to any ICB $(16.7\%$ vs. $3.8\%,$ P = 0.0073)
                      and combined ICB $(14.1\%$ vs. $4.5\%,$ P = 0.017) was more
                      favorable in cohort A. Our data suggest that the combination
                      of LDT with ICB may be associated with a survival benefit
                      and higher treatment response to ICB in patients with
                      metastatic UM.},
      keywords     = {SIRT (Other) / anti-CTLA-4 (Other) / anti-PD-1 (Other) /
                      immune checkpoint blockade (Other) / liver-directed therapy
                      (Other) / uveal melanoma (Other)},
      cin          = {ED01 / A370},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331 / I:(DE-He78)A370-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37432641},
      doi          = {10.1007/s11684-023-0993-y},
      url          = {https://inrepo02.dkfz.de/record/277459},
}